BSBrian M. Slomovitz

Brian M. Slomovitz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Brian M. Slomovitz has a total of 390 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pathologic response and molecular correlates of giredestrant in patients with grade 1 clinical stage IA endometrioid endometrial cancer: the phase II endomERA study

    by Lucy Gilbert, Nimesh Nagarsheth, Susie Lau, Alberto Farolfi, Noelle Cloven, Marcin Misiek, Corby Arthur, Jingyuan Chen, Miranda Craft, Roshni Patel-Romero, et al.

  • Open Access

    Exploratory Biomarker Analysis of Ribociclib Plus Letrozole in Recurrent Low-Grade Serous Carcinoma: A GOG-3026 Correlative Study

    by Kwong-Kwok Wong, Wei Deng, Yvonne Tm Tsang, S. John Weroha, Hye Sook Chon, Vivek Podder, Floor J. Backes, Eric Thomas, Meaghan Elizabeth Tenney, Shannon N. Westin, et al.

    Objective:Ribociclib plus letrozole demonstrated meaningful activity in recurrent low-grade serous ovarian carcinoma (LGSOC) in the phase II GOG-3026 trial. However, predictive biomarkers for CDK4/6 inhibitor response remain undefined. We conducted an exploratory translational analysis to identify molecular and immune biomarkers associated with outcomes. Methods:Archival FFPE tumors from 24 GOG-3026 patients were analyzed. Immunohistochemistry assessed ER, PR, p16, phosphorylated RB (pRB), and Ki-67. Whole-exome sequencing (n=14) and RNA sequencing (n=12) evaluated genomic alterations and immune transcriptional profiles. Associations between biomarkers and objective response rate (ORR), clinical benefit rate (CBR), progression-free survival (PFS) and overall survival were evaluated using 2-sided tests at a 5% significance level, without multiple testing adjustment. Results:Among 24 patients, ORR was 37.5% and CBR was 87.5%. Lower Ki-67 expression was significantly associated with CBR (r = −0.437, p=0.0326). Higher p16 expression showed a trend toward shorter PFS (Cox proportional hazard regression: HR 2.8, 95% CI 0.96–9.20; Monte Carlo permutation log-rank test: p=0.0633). ER, PR, pRB expression and MAPK pathway alterations were not associated with response or survival. The most common genomic alterations involved BRAF, KRAS, NRAS and FANCD2. RNA sequencing identified three immune phenotypes: immune-hot, intermediate, and immune-cold. No partial responders had an immune-hot phenotype, while four of five partial responders clustered in the intermediate group. Conclusions: Lower Ki-67 expression may predict clinical benefit from ribociclib plus letrozole, while higher p16 expression may be associated with shorter PFS. Distinct immune phenotypes may also influence response, supporting prospective validation of proliferation-, cell-cycle-, and immune-based biomarkers to refine patient selection for CDK4/6-directed therapy in LGSOC.

  • Open Access

    Endometrial Cancer by ERBB2 Amplification (ERBB2amp) Status: Differences in Molecular Subtypes, Ancestry, and Real-World Outcomes

    by Evelyn Cantillo, Vivek Podder, Natalie Danziger, Dale Lobo, Douglas I. Lin, Ryon P. Graf, Robert L. Coleman, Bhavana Pothuri, Ramez N. Eskander, Thomas J. Herzog, et al.

    PURPOSE: Endometrial cancer (EC) has rising mortality rates and persistent racial disparities, particularly among non-Hispanic Black women who are more likely to present with aggressive histologic subtypes associated with worse survival. ERBB2 amplification ( ERBB2 amp), a biomarker enriched in aggressive EC subtypes, is a therapeutic target. This study investigates ERBB2 amp prevalence, molecular subtype, and histologic associations, as well as prognostic impact across diverse genetic ancestries using a large clinicogenomic database (CGDB). METHODS: We analyzed 16,073 patients with EC who underwent tissue comprehensive genomic profiling via Foundation Medicine. Genetic ancestry was inferred using a single nucleotide polymorphism–based classifier. An outcomes cohort of 1,275 patients with advanced or recurrent EC from the Flatiron Health-Foundation Medicine CGDB was used to assess survival outcomes. Patients receiving human epidermal growth factor receptor 2 (HER2)–targeted therapy were excluded from the overall survival (OS) analysis. ERBB2 amp prevalence, histologic and molecular correlations, and associations with OS were examined. RESULTS: ERBB2 amp was identified in 8% of EC tumors, with the highest prevalence among patients of African ancestry (12% v 7% European ancestry; P < .001). There was a significant association between ERBB2 amp and serous histology, TP53 mutation presence, low tumor mutational burden, and microsatellite stability. In the outcomes cohort, ERBB2 amp was not independently associated with OS (hazard ratio, 0.88 [95% CI, 0.65 to 1.17]; P = .37). In contrast, TP53mutation and poor performance status were independently associated with decreased OS. Notably, of patients with documented HER2 immunohistochemistry (IHC; n = 305), 22% of nonamplified tumors exhibited HER2 IHC 2+/3+ staining. CONCLUSION: ERBB2 amp is more common among patients with African genetic ancestry and frequently co-occurs with TP53 mutations, providing molecular rationale for EC disparities. Self-reported race does not fully capture genetic ancestry; therefore, comprehensive tumor profiling and HER2 IHC testing should be performed to improve selection for targeted therapies and help address disparities in EC outcomes.

  • Open Access

    Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy

    by Matthew A. Powell, Sharad Ghamande, Lars C. Hanker, Destin Black, Nicoline Raaschou-Jensen, Lucy Gilbert, David Cibula, Angeles Alvarez Secord, Ana Oaknin, Robert W. Holloway, et al.


  • Open Access

    Study outcome and journal impact factor: a meta-epidemiologic analysis of phase III gynecologic oncology trials

    by Gabriel Levin, Emily Eiley, Lucy Gilbert, Bradly J. Monk, Robert L. Coleman, Brian M. Slomovitz, Reitan Ribeiro, Raanan Meyer, Derek Skolnik, Pedro T. Ramirez

  • Top Cited Papers

    Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)

    by Brian M. Slomovitz, S. John Weroha, Wei Deng, Hye Sook Chon, Vivek Podder, Mary Tilley Jenkins Vogel, Floor Backes, Eric D. Thomas, Lee-May Chen, Meaghan Elizabeth Tenney, et al.

    PURPOSE: Low-grade serous carcinoma (LGSOC) of the ovary, fallopian tube, or peritoneum is a hormonally driven, relatively chemoresistant malignancy with limited treatment options in the recurrent setting. Given frequent estrogen receptor (ER) expression and dysregulation of the cyclin-dependent kinases 4 and 6 (CDK4/6)–p16–Rb pathway, features shared with hormone receptor–positive breast cancer, dual endocrine, and CDK4/6 inhibition is a biologically rational strategy. This phase II trial evaluated ribociclib plus letrozole in recurrent LGSOC. METHODS: This open-label, single-arm, multicenter phase II study enrolled women with measurable, recurrent LGSOC. Patients received ribociclib (600 mg orally, once daily, days 1-21 of a 28-day cycle) and letrozole (2.5 mg orally, once daily). The primary end point was investigator-assessed objective response rate (ORR) per RECIST 1.1. Secondary end points included clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Of 74 patients screened, 51 were enrolled and 49 treated. The confirmed ORR was 30.6% (90% CI, 19.9 to 43.2), including one complete and 14 partial responses. Among responders, the median duration of response was 21.2 months. The CBR was 84% (90% CI, 72.5 to 91.6). The median PFS was 14.5 months (90% CI, 10.1 to 28.8), and the median OS was 44.5 months (90% CI, 31.8 to not reached). The most common grade ≥3 adverse event (AE) was neutropenia (47%), managed with dose modifications. Three grade 5 events (6%) occurred but were unrelated to treatment. Treatment discontinuation because of AEs occurred in 4%. No dose-limiting toxicities were observed. CONCLUSION: Ribociclib plus letrozole met the primary end point, achieving meaningful response rates and durable disease control in recurrent LGSOC. The safety profile was consistent with prior CDK4/6 inhibitor studies. This combination represents a therapeutic option in this rare and genomically distinct subtype.


  • Open Access

    Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial

    by Kan Yonemori, Shin Nishio, Shiro Suzuki, Kosei Hasegawa, Mayu Yunokawa, Satoshi Yamaguchi, Aikou Okamoto, Kazuto Nakamura, Shoji Kamiura, Keiichi Fujiwara, et al.


  • Homologous recombination deficiency in endometrial cancer: shedding light on recent clinical findings

    by Griffin Willman, Vivek Podder, Shannon Neville Westin, Bradley R. Corr, Robert L. Coleman, Bhavana Pothuri, Kathleen N. Moore, Brian M. Slomovitz


  • Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities

    by Vivek Podder, Robert L. Coleman, Andrea R. Hagemann, Priya Singhania, Matthew A. Powell, Thomas J. Herzog, Brian M. Slomovitz

    Endometrial cancer incidence and mortality are rising globally, largely driven by the obesity epidemic. Treatment options remain limited for obesity-associated, hormone-resistant, or fertility-preserving endometrial cancer, highlighting the need for novel therapies that address both tumor biology and metabolic dysfunction. In this study, we synthesize the molecular rationale, preclinical, population-based, and emerging clinical trial evidence on glucagon-like peptide-1 receptor (GLP-1R) agonists (GLP-1 RA) in endometrial cancer. GLP-1R is expressed in benign and malignant endometrial tissues, where activation of cAMP–PKA and AMPK–mTOR signaling has been shown to mediate antiproliferative, proapoptotic, and autophagy-inducing effects. Preclinical models demonstrate that class-wide GLP-1 RAs may restore progesterone receptor expression, overcome hormone resistance, and synergize with progestin therapy; however, the effects may vary by agent. Retrospective studies suggest that combining GLP-1 RAs with local progestin therapy, commonly a levonorgestrel-releasing intrauterine device (preferred in obesity because oral progestin bioavailability is reduced), is associated with a reduced risk of endometrial cancer in high-risk women. Ongoing clinical trials are assessing their role in fertility-sparing settings—evaluating complete response to progestin-based therapy, relapse rates, and time to conception outcomes—as well as in adjuvant settings, in which disease-free survival is a key endpoint; however, gastrointestinal tolerability and the absence of long-term safety data in endometrial cancer populations remain important considerations. As a class, GLP-1 RAs represent a promising therapeutic approach to targeting both the obesogenic milieu and tumor-intrinsic pathways in endometrial cancer; however, agent-specific differences warrant attention. Prospective, subtype-stratified trials are essential to establish their role in comprehensive endometrial cancer care.